Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives

European Journal of Cancer

Volumn 59, Issue , 2016, Pages 160-170

  Moehler, Markus ^a   Delic, Maike ^a   Goepfert, Katrin ^a   Aust, Daniela ^b   Grabsch, Heike I ^c,d   Halama, Niels ^e   Heinrich, Bernd ^a   Julie, Catherine ^f   Lordick, Florian ^g   Lutz, Manfred P ^h   Mauer, Murielle ⁱ   Alsina Maqueda, Maria ^j   Schild, Hansjoerg ^a   Schimanski, Carl C ^k   Wagner, Anna Dorothea ^l   Roth, Arnaud ^m   Ducreux, Michel ⁿ  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^f HÔPITAL AMBROISE PARÉ   (France)

^g UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^h Department of Obstetrics/Gynecology   (Germany)

ⁱ EORTC DATA CENTER   (Belgium)

^j VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^k Marien Hospital Darmstadt   (Germany)

^l LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^m UNIVERSITY OF GENEVA   (Switzerland)

ⁿ INSTITUT GUSTAVE ROUSSY   (France)

more..

Author keywords

Checkpoint inhibitors; Gastrointestinal cancer; Immunotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; ATEZOLIZUMAB; AVELUMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DURVALUMAB; IPILIMUMAB; LEFITOLIMOD; NIVOLUMAB; ONCOLYTIC VIRUS; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; TICILIMUMAB; GENETIC MARKER; MONOCLONAL ANTIBODY; TUMOR MARKER;

ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; CELL DENSITY; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; GENETIC MARKER; HUMAN; LYMPHOCYTIC INFILTRATION; MISMATCH REPAIR; ONCOLYTIC VIROTHERAPY; PERSONALIZED MEDICINE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; CELL CYCLE CHECKPOINT; DRUG EFFECTS; EPIDEMIOLOGY; FORECASTING; GASTROINTESTINAL NEOPLASMS; IMMUNOTHERAPY; METABOLISM; MOLECULARLY TARGETED THERAPY; PHYSIOLOGY; PROCEDURES; TREATMENT OUTCOME; TRENDS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CELL CYCLE CHECKPOINTS; EPIDEMIOLOGIC METHODS; FORECASTING; GASTROINTESTINAL NEOPLASMS; GENETIC MARKERS; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; ONCOLYTIC VIROTHERAPY; TREATMENT OUTCOME;

EID: 84961967609     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2016.02.020     Document Type: Review

References (76)

1. M.S. Barbee, A. Ogunniyi, T.Z. Horvat, and T.O. Dang Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology Ann Pharmacother 49 8 2015 907 937
2. A. Ito, S. Kondo, K. Tada, and S. Kitano Clinical development of immune checkpoint inhibitors Biomed Res Int 2015 2015 605478
3. E.B. Garon, N.A. Rizvi, R. Hui, N. Leighl, A.S. Balmanoukian, J.P. Eder, and et al. Pembrolizumab for the treatment of non-small-cell lung cancer N Engl J Med 372 21 2015 2018 2028
4. C. Ralph, E. Elkord, D.J. Burt, J.F. O'Dwyer, E.B. Austin, P.L. Stern, and et al. Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma Clin Cancer Res 16 5 2010 1662 1672
5. J.D. Wolchok, A. Hoos, S. O'Day, J.S. Weber, O. Hamid, C. Lebbe, and et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria Clin Cancer Res 15 23 2009 7412 7420
6. J. Wang, K.A. Reiss, R. Khatri, E. Jaffee, and D. Laheru Immune therapy in GI malignancies: a review J Clin Oncol 33 16 2015 1745 1753
7. P. van der Bruggen, C. Traversari, P. Chomez, C. Lurquin, E. De Plaen, B. Van den Eynde, and et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma Science 254 5038 1991 1643 1647
8. S.K. Nair, M. Morse, D. Boczkowski, R.I. Cumming, L. Vasovic, E. Gilboa, and et al. Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells Ann Surg 235 4 2002 540 549
9. M.Y. Mapara, and M. Sykes Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance J Clin Oncol 22 6 2004 1136 1151
10. E.Y. Woo, H. Yeh, C.S. Chu, K. Schlienger, R.G. Carroll, J.L. Riley, and et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation J Immunol 168 9 2002 4272 4276
11. I. Mellman Dendritic cells: master regulators of the immune response Cancer Immunol Res 1 3 2014 145 149
12. N. Lapteva, M.R. Seethammagari, B.A. Hanks, J. Jiang, J.M. Levitt, K.M. Slawin, and et al. Enhanced activation of human dendritic cells by inducible CD40 and toll-like receptor-4 ligation Cancer Res 67 21 2007 10528 10537
13. K. Shimizu, Y. Kotera, A. Aruga, N. Takeshita, S. Katagiri, S. Ariizumi, and et al. Postoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma Hum Vaccin Immunother 10 4 2014 970 976
14. S.A. Rosenberg Raising the bar: the curative potential of human cancer immunotherapy Sci Transl Med 4 127 2012 127ps8
15. I. Puzanov, M.M. Milhem, R. Andtbacka, D. Minor, O. Hamid, A. Li, and et al. Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIBIV melanoma ASCO Annual Meeting J Clin Oncol 32 5s 2014
16. S. Walter, T. Weinschenk, A. Stenzl, R. Zdrojowy, A. Pluzanska, C. Szczylik, and et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival Nat Med 18 8 2012 1254 1261
17. T. Wolfel, J.C. Becker, and M. Schmitt Immune oncology in focus Onkologie 36 Suppl. 4 2013 7 11
18. I.K. Choi, R. Strauss, M. Richter, C.O. Yun, and A. Lieber Strategies to increase drug penetration in solid tumors Front Oncol 3 2013 193
19. Y. Wu, H. Grabsch, T. Ivanova, I.B. Tan, J. Murray, C.H. Ooi, and et al. Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer Gut 62 8 2012 1100 1111
20. J.G. Kim, B.W. Kang, and S. Yoon PD-001 Prognostic value of tumor infiltrating lymphocytes (TILs) in Epstein-Barr virus (EBV)-associated gastric cancer (EBVaGC) Ann Oncol 26 Suppl. 4 2015 iv101
21. J. Galon, A. Costes, F. Sanchez-Cabo, A. Kirilovsky, B. Mlecnik, C. Lagorce-Pages, and et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome Science 313 5795 2006 1960 1964
22. N. Halama, S. Michel, M. Kloor, I. Zoernig, A. Benner, A. Spille, and et al. Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy Cancer Res 71 17 2011 5670 5677
23. E. Tanis, C. Julie, J.F. Emile, M. Mauer, B. Nordlinger, D. Aust, and et al. Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983 Eur J Cancer 51 17 2015 2708 2717
24. H.J. Schmoll, B. Wittig, D. Arnold, J. Riera-Knorrenschild, D. Nitsche, H. Kroening, and et al. Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial J Cancer Res Clin Oncol 140 9 2014 1615 1624
25. B. Wittig, M. Schmidt, W. Scheithauer, and H.J. Schmoll MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: from bench to bedside Crit Rev Oncol Hematol 94 1 2015 31 44
26. C. Reissfelder, S. Stamova, C. Gossmann, M. Braun, A. Bonertz, U. Walliczek, and et al. Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis J Clin Invest 125 2 2015 739 751
27. J.M. Taube, A. Klein, J.R. Brahmer, H. Xu, X. Pan, J.H. Kim, and et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy Clin Cancer Res 20 19 2014 5064 5074
28. S.L. Topalian, F.S. Hodi, J.R. Brahmer, S.N. Gettinger, D.C. Smith, D.F. McDermott, and et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 26 2012 2443 2454
29. L. Carbognin, S. Pilotto, M. Milella, V. Vaccaro, M. Brunelli, A. Calio, and et al. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (pd-l1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers PLoS One 10 6 2015 e0130142
30. C.C. Schimanski, R. Bahre, I. Gockel, A. Muller, K. Frerichs, V. Horner, and et al. Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4 Br J Cancer 95 2 2006 210 217
31. C.C. Schimanski, S. Schwald, N. Simiantonaki, C. Jayasinghe, U. Gonner, V. Wilsberg, and et al. Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer Clin Cancer Res 11 5 2005 1743 1750
32. C.C. Schimanski, P.R. Galle, and M. Moehler Chemokine receptor CXCR4-prognostic factor for gastrointestinal tumors World J Gastroenterol 14 30 2008 4721 4724
33. T. Thomaidis, A. Maderer, S.E. Al-Batran, J. Kany, C. Pauligk, K. Steinmetz, and et al. VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) BMC Cancer 14 2014 476
34. C.C. Schimanski, M. Mohler, M. Schon, E. van Cutsem, R. Greil, W.O. Bechstein, and et al. LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial BMC Cancer 12 2012 144
35. Ci3 Identification and development of biomarkers for a specific immune response to L-BLP25, an antigen-specific cancer immunotherapy Cluster for Individualized Immune Intervention (Ci3) 2012 Biomarker discovery strategy
36. S. Kreiter, M. Vormehr, N. van de Roemer, M. Diken, M. Lower, J. Diekmann, and et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer Nature 520 7549 2015 692 696
37. V. Boisguerin, J.C. Castle, M. Loewer, J. Diekmann, F. Mueller, C.M. Britten, and et al. Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside Br J Cancer 111 8 2014 1469 1475
38. B.-P. Kloke, C.M. Britten, C. Loquai, M. Löwer, S. Attig, V. Bukur, and et al. Abstract CT202: IVAC MUTANOME: Individualized vaccines for the treatment of cancer Cancer Res 75 15 Suppl 2015 CT202
39. Y. Qing, Q. Li, T. Ren, W. Xia, Y. Peng, G.L. Liu, and et al. Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer Drug Des Devel Ther 9 2015 901 909
40. K. Muro, Y.J. Bang, V. Shankaran, R. Geva, D.V. Catenacci, S. Gupta, and et al. Relationship between PD-L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-012 ASCO Annual Meeting J Clin Oncol 33 2015
41. J. Larkin, V. Chiarion-Sileni, R. Gonzalez, J.J. Grob, C.L. Cowey, C.D. Lao, and et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma N Engl J Med 373 1 2015 23 34
42. Comprehensive molecular characterization of gastric adenocarcinoma Nature 513 7517 2014 202 209
43. R. Dienstmann, J. Guinney, M. Delorenzi, A. De Reynies, P. Roepman, A. adanandam, and et al. Colorectal Cancer Subtyping Consortium (CRCSC) identification of a consensus of molecular subtypes ASCO Annual Meeting: J Clin Oncol 32 5s 2014
44. R. Dienstmann, R. Salazar, and J. Tabernero Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients J Clin Oncol 33 16 2015 1787 1796
45. D.T. Le, J.N. Uram, H. Wang, B.R. Bartlett, H. Kemberling, A.D. Eyring, and et al. PD-1 Blockade in tumors with mismatch-repair deficiency N Engl J Med 372 26 2015 2509 2520
46. H. Kim, J. Jen, B. Vogelstein, and S.R. Hamilton Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences Am J Pathol 145 1 1994 148 156
47. G. Poulogiannis, I.M. Frayling, and M.J. Arends DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome Histopathology 56 2 2010 167 179
48. R.H. Andtbacka, H.L. Kaufman, F. Collichio, T. Amatruda, N. Senzer, J. Chesney, and et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma J Clin Oncol 33 25 2015 2780 2788
49. B.D. Lichty, C.J. Breitbach, D.F. Stojdl, and J.C. Bell Going viral with cancer immunotherapy Nat Rev Cancer 14 8 2014 559 567
50. J.J. Rojas, P. Sampath, W. Hou, and S.H. Thorne Defining effective combinations of immune checkpoint blockade and oncolytic virotherapy Clin Cancer Res 21 24 2015 5543 5551
51. G.G. Au, L.G. Beagley, E.S. Haley, R.D. Barry, and D.R. Shafren Oncolysis of malignant human melanoma tumors by Coxsackieviruses A13, A15 and A18 Virol J 8 2011 22
52. D. Zamarin, R.B. Holmgaard, S.K. Subudhi, J.S. Park, M. Mansour, P. Palese, and et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy Sci Transl Med 6 226 2014 226ra32
53. E. Calvo, M. Gil-Martin, J.-P.H. Machiels, S. Rottey, A. Cubillo, R. Salazar, and et al. A first-in-class, first-in-human phase I study of enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus, administered intravenously in patients with metastatic epithelial tumors 2014 ASCO Annual Meeting: J Clin Oncol 32 5s 2014 2014 (suppl; abstr 3103)
54. V. Boni, F. Portilla, A. Cubillo, M. Martin, E. Calvo, R. Salazar, and et al. A phase 1 mechanism of action study of intra-tumoural (IT) or intravenous (IV) administration of enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus in colon cancer patients undergoing resection of primary tumour Ann Oncol 25 Suppl. 4 2014 iv368
55. J. Burke, J. Nieva, M.J. Borad, and C.J. Breitbach Oncolytic viruses: perspectives on clinical development Curr Opin Virol 13 2015 55 60
56. J. Heo, T. Reid, L. Ruo, C.J. Breitbach, S. Rose, M. Bloomston, and et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer Nat Med 19 3 2013 329 336
57. H.L. Kaufman, D.W. Kim, G. DeRaffele, J. Mitcham, R.S. Coffin, and S. Kim-Schulze Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma Ann Surg Oncol 17 3 2009 718 730
58. M.H. Moehler, M. Zeidler, V. Wilsberg, J.J. Cornelis, T. Woelfel, J. Rommelaere, and et al. Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells Hum Gene Ther 16 8 2005 996 1005
59. A. Marchini, S. Bonifati, E.M. Scott, A.L. Angelova, and J. Rommelaere Oncolytic parvoviruses: from basic virology to clinical applications Virol J 12 2015 6
60. M. Moehler, M. Sieben, S. Roth, F. Springsguth, B. Leuchs, M. Zeidler, and et al. Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1 BMC Cancer 11 2011 464
61. M. Sieben, P. Schafer, C. Dinsart, P.R. Galle, and M. Moehler Activation of the human immune system via toll-like receptors by the oncolytic parvovirus H-1 Int J Cancer 132 11 2013 2548 2556
62. M. Moehler, H.C. Lee, W.Y. Tak, Y. Chao, S.W. Paik, A. Baron, and et al. Randomized Phase IIb study of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncoloytic immunotherapy plus best supportive care (BSC) versus BSC alone in patients with hepatocellular carcinoma (HCC) who failed sorafenib treatment (Traverse) ILCA 9th Annual Conference Paris, France 2015
63. C.J. Breitbach, K. Parato, J. Burke, T.H. Hwang, J.C. Bell, and D.H. Kirn Pexa-Vec double agent engineered vaccinia: oncolytic and active immunotherapeutic Curr Opin Virol 13 2015 49 54
64. I.M. Modlin, M. Kidd, T. Hinoue, K.D. Lye, J. Murren, and A. Argiris Molecular strategies and 111in-labelled somatostatin analogues in defining the management of neuroendocrine tumour disease: a new paradigm for surgical management Surgeon 1 3 2003 137 143
65. M.H. den Brok, R.P. Sutmuller, S. Nierkens, E.J. Bennink, L.W. Toonen, C.G. Figdor, and et al. Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine Cancer Res 66 14 2006 7285 7292
66. J.S. Weber, J.C. Yang, M.B. Atkins, and M.L. Disis Toxicities of immunotherapy for the practitioner J Clin Oncol 33 18 2015 2092 2099
67. S. Aspeslagh, S. Postel-Vinay, S. Rusakiewicz, J.C. Soria, L. Zitvogel, and A. Marabelle Rationale for anti-OX40 cancer immunotherapy Eur J Cancer 52 2016 50 66
68. B.D. Curti, M. Kovacsovics-Bankowski, N. Morris, E. Walker, L. Chisholm, K. Floyd, and et al. OX40 is a potent immune-stimulating target in late-stage cancer patients Cancer Res 73 24 2013 7189 7198
69. A.C. Anderson Tim-3: an emerging target in the cancer immunotherapy landscape Cancer Immunol Res 2 5 2014 393 398
70. L.T. Nguyen, and P.S. Ohashi Clinical blockade of PD1 and LAG3-potential mechanisms of action Nat Rev Immunol 15 1 2015 45 56
71. S.R. Woo, M.E. Turnis, M.V. Goldberg, J. Bankoti, M. Selby, C.J. Nirschl, and et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape Cancer Res 72 4 2012 917 927
72. M.E. Turnis, L.P. Andrews, and D.A. Vignali Inhibitory receptors as targets for cancer immunotherapy Eur J Immunol 45 7 2015 1892 1905
73. K. Baksh, and J. Weber Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinations Semin Oncol 42 3 2015 363 377
74. O. Bohnsack, A. Hoos, and K. Ludajic Adaptation and modification of the immune related response criteria (IRRC): IrRECIST ASCO Annual Meeting: J Clin Oncol 32 2014
75. T.T. Chen Statistical issues and challenges in immuno-oncology J Immunother Cancer 1 2013 18
76. A. Hoos, A.M. Eggermont, S. Janetzki, F.S. Hodi, R. Ibrahim, A. Anderson, and et al. Improved endpoints for cancer immunotherapy trials J Natl Cancer Inst 102 18 2010 1388 1397